keyword
MENU ▼
Read by QxMD icon Read
search

cytarabine

keyword
https://www.readbyqxmd.com/read/29452671/what-is-the-optimal-initial-management-of-the-younger-mantle-cell-lymphoma-patient
#1
REVIEW
Rory McCulloch, Simon Rule
The last 20 years has seen considerable advances made in the management of younger patients with mantle cell lymphoma. The use of high dose cytarabine and rituximab in induction therapy, usually followed by autologous stem cell transplant consolidation, has become established practice and the median overall survival now exceeds 10 years. However, this high intensity upfront approach is not necessarily appropriate for all newly diagnosed patients. A minority exhibit disease that behaves in an indolent fashion with no proven benefit from early intervention, and at the opposite end of the spectrum a high-risk group exists who do poorly with conventional treatment...
March 2018: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29437791/a-phase-i-study-of-cpi-613-in-combination-with-high-dose-cytarabine-and-mitoxantrone-for-relapsed-or-refractory-acute-myeloid-leukemia
#2
Timothy S Pardee, Rebecca G Anderson, Kristin M Pladna, Scott Isom, Lais P Ghiraldeli, Lance D Miller, Jeff A Chou, Guangxu Jin, Wei Zhang, Leslie R Ellis, Dmitriy Berenzon, Dianna S Howard, David Hurd, Megan Manuel, Sarah Dralle, Susan Lyerly, Bayard L Powell
PURPOSE: CPI-613, a lipoate analog that inhibits pyruvate dehydrogenase (PDH) and α-ketogluterate dehydrogenase (KGDH) has activity in patients with myeloid malignancies. This study explored the role of mitochondrial metabolism in chemotherapy response, determined the maximally tolerated dose, efficacy and safety of CPI-613 combined with high dose cytarabine and mitoxantrone in patients with relapsed or refractory acute myeloid leukemia. METHODS: The role of mitochondrial response to chemotherapy was assessed in cell lines and animal models...
February 6, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29435190/experiment-research-of-focused-ultrasound-combined-with-drug-and-microbubble-for-treatment-of-central-nervous-system-leukemia
#3
Xiao-Ping Xi, Yu-Jin Zong, Yan-Hong Ji, Bing Wang, Hua-Sheng Liu
It has been shown that low frequency ultrasound in the presence of microbubble can effectively open the blood brain barrier (BBB) to allow the drugs to be delivered into the brain with an increased concentration. We aim to apply this method to increase the efficacy of Cytarabine (Ara-c) to treat central nervous system leukemia (CNSL). In the present study, we validated this ultrasound contrast agent Sonovue® targeting treatment via in vivo and in vitro experiments. The results showed that Sonovue® combined with Cytarabine could significantly inhibit K562 cell (chronic myeloid leukemia cell line) proliferation...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29435104/niclosamide-suppresses-acute-myeloid-leukemia-cell-proliferation-through-inhibition-of-creb-dependent-signaling-pathways
#4
Hee-Don Chae, Nick Cox, Gary V Dahl, Norman J Lacayo, Kara L Davis, Samanta Capolicchio, Mark Smith, Kathleen M Sakamoto
CREB (cAMP Response Element Binding protein) is a transcription factor that is overexpressed in primary acute myeloid leukemia (AML) cells and associated with a decreased event-free survival and increased risk of relapse. We recently reported a small molecule inhibitor of CREB, XX-650-23, which inhibits CREB activity in AML cells. Structure-activity relationship analysis for chemical compounds with structures similar to XX-650-23 led to the identification of the anthelminthic drug niclosamide as a potent anti-leukemic agent that suppresses cell viability of AML cell lines and primary AML cells without a significant decrease in colony forming activity of normal bone marrow cells...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29433979/marrow-hypocellularity-but-not-residual-blast-count-or-receipt-of-reinduction-chemotherapy-is-prognostic-on-day-14-assessment-in-acute-myeloid-leukemia-patients-with-morphologic-residual-disease
#5
Thomas A Ollila, Adam J Olszewski, James N Butera, Matthew I Quesenberry, Peter J Quesenberry, John L Reagan
BACKGROUND: Induction chemotherapy for acute myeloid leukemia (AML) is based on the "7+3" cytarabine/anthracycline regimen. A nonhypocellular day 14 (D14) bone marrow sample with a blast count > 5% to 10% is suggestive of residual leukemia, for which a second course of induction chemotherapy has been recommended. Although the prognostic value of D14 bone marrow findings has been established, its use as a decision point is controversial because the benefit of repeat induction has been questioned...
January 31, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29429247/-clinical-research-on-acute-paraplegia-resulting-from-intrathecal-chemotherapy
#6
M Cheng, L Xue, Y J Li, Q Jiang, J Zhang, X G Gao
Objective: To investigate the potential pathogenesis of acute paraplegia resulting from intrathecal chemotherapy and to analyze the factors influencing prognosis. Methods: Six cases presented with acute paraplegia after intrathecal chemotherapy for leukemia from January 1(st,) 2015 to June 1(st,) 2017 in our hospital. The patients' clinical manifestation, data of imaging and cerebrospinal fluid were analyzed. Result: Six patients with leukemia were with an average age of 27.3 (7 to 55) years old. Four cases were intrathecally injected with cytarabine, and two cases were intrathecally injected with cytarabine and methotrexate...
January 30, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29423065/phosphatase-of-regenerating-liver-3-is-expressed-in-acute-lymphoblastic-leukemia-and-mediates-leukemic-cell-adhesion-migration-and-drug-resistance
#7
Magnus A Hjort, Pegah Abdollahi, Esten N Vandsemb, Mona H Fenstad, Bendik Lund, Tobias S Slørdahl, Magne Børset, Torstein B Rø
Phosphatase of regenerating liver-3 (PRL-3/PTP4A3) is upregulated in multiple cancers, including BCR-ABL1- and ETV6-RUNX-positive acute lymphoblastic leukemia (ALL). With this study, we aim to characterize the biological role of PRL-3 in B cell ALL (B-ALL). Here, we demonstrate that PRL-3 expression at mRNA and protein level was higher in B-ALL cells than in normal cells, as measured by qRT-PCR or flow cytometry. Further, we demonstrate that inhibition of PRL-3 using shRNA or a small molecular inhibitor reduced cell migration towards an SDF-1α gradient in the preB-ALL cell lines Reh and MHH-CALL-4...
January 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29416652/phase-ii-study-of-rituximab-given-in-conjunction-with-standard-chemotherapy-in-primary-central-nervous-system-lymphoma-pcnsl-a-trial-of-the-ecog-acrin-cancer-research-group-e1f05
#8
Lode J Swinnen, Anne O'Neill, Philip H Imus, Sachin Gujar, David Schiff, Lawrence R Kleinberg, Ranjana H Advani, Erin M Dunbar, Dennis Moore, Stuart A Grossman
Background: Therapy of primary CNS lymphoma (PCNSL) has focused on multi-agent chemotherapy designed to cross the blood brain barrier. Rituximab has demonstrated activity in PCNSL. E1F05 is an ECOG-ACRIN multicenter phase 2 prospective trial of rituximab with high-dose methotrexate (HD-MTX)-based chemotherapy similar to the RTOG 93-10 regimen, omitting radiotherapy. Methods: Immunocompetent patients with newly diagnosed PCNSL received HD-MTX 3.5g/m2 with vincristine every two weeks for 5 doses; procarbazine for 7 days in weeks 1, 5, and 9; cytarabine 3g/m2/day IV for 2 days in weeks 11 and 14; a dexamethasone taper over 6 weeks; and rituximab 375mg/m2 IV infusion 3 times per week for weeks 1-4...
January 2, 2018: Oncotarget
https://www.readbyqxmd.com/read/29416633/allogeneic-hematopoietic-stem-cell-transplantation-for-relapsed-acute-myeloid-leukemia-in-eto-positive-with-reduced-intensity-conditioning
#9
Zhi Guo, Chen Xu, Hu Chen
Objective: This research is conducted under the intention of exploring the efficacy and safety of reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of relapsed ETO positive acute myeloid leukemia (AML). Materials and Methods: Treatment of 15 cases referring to recurrent ETO positive acute myeloid leukemia in an army hospital from January 2010 to January 2013 through allo-HSCT with reduced-intensity conditioning...
January 2, 2018: Oncotarget
https://www.readbyqxmd.com/read/29415941/-neurolymphomatosis-due-to-enteropathy-associated-t-cell-lymphoma-clinically-diagnosed-by-fdg-pet-ct-and-subsequently-confirmed-by-autopsy
#10
Nozomu Uematsu, Masahiko Sumi, Hiroko Kaiume, Wataru Takeda, Takehiko Kirihara, Toshimitsu Ueki, Yuki Hiroshima, Mayumi Ueno, Naoaki Ichikawa, Masahide Watanabe, Hikaru Kobayashi
A 59-year-old man who complained of abdominal pain was referred to our hospital. Computed tomography (CT) revealed mesenteric lymph node swelling and intestinal perforation. Histopathological study of the resected ileum and lymph node demonstrated diffuse proliferation of medium-sized atypical lymphocytes. Immunohistochemistry results were positive for cluster of differentiation (CD) 3, CD8, and CD56 cells, negative for CD5 and CD4 cells, and negative for Epstein-Barr virus-encoded RNA-fluorescent in situ hybridization (EBER-FISH)...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29415603/a-real-world-study-of-clofarabine-and-cytarabine-combination-therapy-for-patients-with-acute-myeloid-leukemia
#11
Fiona He, Smarika Sapkota, Sarah Parker, Todd Defor, Erica Warlick, Celalettin Ustun, Craig Eckfeldt, Armin Rashidi, Andy Kurtzweil, Daniel Weisdorf, Nelli Bejanyan
Clofarabine and cytarabine (Clo + Ara-C) combinations have efficacy in treatment of acute myeloid leukemia (AML). We retrospectively analyzed clinical outcomes of 71 AML patients receiving Clo + Ara-C regimens at the University of Minnesota from 2011 to 2016: 44 patients (62%) had newly diagnosed AML and 27 patients (38%) had relapsed/refractory AML. The median age of patients was 69 years (interquartile range [IQR], 63-75 years). Nearly 60% of the patients had secondary AML, and about half of patients had adverse risk cytogenetics...
February 7, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29407318/treatment-of-high-risk-acute-myeloid-leukemia-with-cladribine-cytarabine-mitoxantrone-and-granulocyte-colony-stimulating-factor-then-subsequent-bridging-to-myeloablative-allogeneic-hematopoietic-stem-cell-transplantation-a-case-series
#12
J Zhang, Y Sun, X Zhang, B Long, Y Lu, X Li
This report preliminarily evaluates the efficacy and safety of cladribine, cytarabine, mitoxantrone, and granulocyte colony-stimulating factor (CLAG-M) as bridging therapy to myeloablative allogeneic hematopoietic cell transplantation (allo-HCT) in the treatment of patients with refractory or relapsed acute myeloid leukemia. Five patients with high-risk refractory or relapsed acute myeloid leukemia received the CLAG-M regimen and subsequent bridging to myeloablative allo-HCT between December 2014 and August 2015 in our hospital...
January 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29407182/report-of-the-relapsed-refractory-cohort-of-swog-s0919-a-phase-2-study-of-idarubicin-and-cytarabine-in-combination-with-pravastatin-for-acute-myelogenous-leukemia-aml
#13
Anjali S Advani, Hongli Li, Laura C Michaelis, Bruno C Medeiros, Michaela Liedtke, Alan F List, Kristen O'Dwyer, Megan Othus, Harry P Erba, Frederick R Appelbaum
Inhibition of cholesterol synthesis and uptake sensitizes acute myeloid leukemia (AML) blasts to chemotherapy. A Phase 2 study of high dose pravastatin given in combination with idarubicin and cytarabine demonstrated an impressive response rate [75% complete remission (CR), CR with incomplete count recovery (CRi)]. However, this population was a favorable risk group as eligible patients had to have a CR/CRi lasting ≥3 months following their most recent chemotherapy. Therefore, the study was amended to treat patients with poor risk disease including those with CR/CRi <6 months following their last induction regimen or with refractory disease...
January 31, 2018: Leukemia Research
https://www.readbyqxmd.com/read/29399180/characteristics-of-doxorubicin-selected-multidrug-resistant-human-leukemia-hl-60-cells-with-tolerance-to-arsenic-trioxide-and-contribution-of-leukemia-stem-cells
#14
Jing Chen, Hulai Wei, Jie Cheng, Bei Xie, Bei Wang, Juan Yi, Baoying Tian, Zhuan Liu, Feifei Wang, Zhewen Zhang
The present study selected and characterized a multidrug-resistant HL-60 human acute promyelocytic leukemia cell line, HL-60/RS, by exposure to stepwise incremental doses of doxorubicin. The drug-resistant HL-60/RS cells exhibited 85.68-fold resistance to doxorubicin and were cross-resistant to other chemotherapeutics, including cisplatin, daunorubicin, cytarabine, vincristine and etoposide. The cells over-expressed the transporters P-glycoprotein, multidrug-resistance-related protein 1 and breast-cancer-resistance protein, encoded by the adenosine triphosphate-binding cassette (ABC)B1, ABCC1 and ABCG2 genes, respectively...
January 2018: Oncology Letters
https://www.readbyqxmd.com/read/29397824/-clinical-efficacy-of-decitabine-combined-with-or-without-cytarabine-based-low-dose-regimen-for-senile-patients-with-acute-myeloid-leukemia
#15
Hong-Wei Zhou, Min-Hang Zhou, Zhi-Hong Wang, Peng-Fei Li, Mo Liu, Yu DU, Yi-Bing Yao, Chao-Jin Peng, Yu Jing, Jun-Zhong Sun
OBJECTIVE: To investigate the therapeutic effectiveness and side effects of decitabine combined with or without cytarabine-based low dose regimen for acute myeloid leukemia in geratic patients. METHODS: Clinical data of 8 geratic patients (aged over 70 years) suffered from acute myeloid leukemia from September 2009 to March 2012 were analyzed retrospectively, including age, sex, peripheral blood and bone marrow characteristics and so on. These patients were treated by an 1-hour intravenous infusion of decitabine 20 mg/m2 per day for 5 consecutive days every 4 weeks combined with or without low dose regimen dominantly consisting of cytarabine 20 mg per day as subcutaneous injection for seven consecutive days...
February 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29396857/flai-fludarabine-cytarabine-idarubicin-plus-low-dose-gemtuzumab-ozogamicin-as-induction-therapy-in-cd33-positive-aml-final-results-and-long-term-outcome-of-a-phase-ii-multicenter-clinical-trial
#16
Anna Candoni, Cristina Papayannidis, Giovanni Martinelli, Erica Simeone, Michele Gottardi, Ilaria Iacobucci, Filippo Gherlinzoni, Giuseppe Visani, Michele Baccarani, Renato Fanin
The aim of this prospective clinical trial was to evaluate the efficacy and safety of a combination of Gemtuzumab-Ozogamicin (GO) and FLAI scheme (fludarabine, cytarabine, idarubicin) as a first-line therapy in CD33 positive acute myeloid leukemia (AML). We treated 130 consecutive patients, aged <65, with a median age of 52 years (range, 18-65). FLAI-GO induction regimen included fludarabine (30 mg/sqm) and cytarabine (2 g/sqm) on days 1-5; idarubicin (10 mg/sqm) on days 1, 3, and 5; and GO (3 mg/sqm) on day 6...
February 2, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29392425/a-phase-i-ii-study-of-plerixafor-in-combination-with-fludarabine-idarubicin-cytarabine-and-g-csf-pleriflag-regimen-for-the-treatment-of-patients-with-the-first-early-relapsed-or-refractory-acute-myeloid-leukemia
#17
David Martínez-Cuadrón, Blanca Boluda, Pilar Martínez, Juan Bergua, Rebeca Rodríguez-Veiga, Jordi Esteve, Susana Vives, Josefina Serrano, Belen Vidriales, Olga Salamero, Lourdes Cordón, Amparo Sempere, Ana Jiménez-Ubieto, Julio Prieto-Delgado, Marina Díaz-Beyá, Ana Garrido, Celina Benavente, José Antonio Pérez-Simón, Federico Moscardó, Miguel A Sanz, Pau Montesinos Fernández
Clinical outcomes of patients with acute myeloid leukemia (AML) showing the first primary refractory or early-relapsed disease remain very poor. The Programa Español de Tratamientos en Hematología (PETHEMA) group designed a phase I-II trial using FLAG-Ida (fludarabine, idarubicin, cytarabine, and G-CSF) plus high-dose intravenous plerixafor, a molecule inducing mobilization of blasts through the SDF-1α-CXCR4 axis blockade and potentially leading to chemosensitization of the leukemic cells. We aimed to establish a recommended phase 2 dose (RP2D) of plerixafor plus FLAG-Ida, as well as the efficacy and safety of this combination for early-relapsed (first complete remission (CR/CRi) < 12 months) or primary refractory AML...
February 2, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29390048/intermediate-dose-cytarabine-plus-mitoxantrone-versus-standard-dose-cytarabine-plus-daunorubicine-for-acute-myeloid-leukemia-in-elderly-patients
#18
C Röllig, M Kramer, M Gabrecht, M Hänel, R Herbst, U Kaiser, N Schmitz, J Kullmer, S Fetscher, H Link, L Mantovani-Löffler, U Krümpelmann, T Neuhaus, F Heits, H Einsele, B Ritter, M Bornhäuser, J Schetelig, C Thiede, B Mohr, M Schaich, U Platzbecker, K Schäfer-Eckart, A Krämer, W E Berdel, H Serve, G Ehninger, U Schuler
Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7 + 3 induction regimen consisting of continuous infusion daunorubicin plus cytarabine (DA). Patients and methods: Patients with newly diagnosed AML >60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m2 BID days 1,3,5,7) plus mitoxantrone (10 mg/m2 days 1-3) (IMA) or standard induction therapy with cytarabine (100 mg/m2 continuously days 1-7) plus daunorubicin (45 mg/m2 days 3-5) (DA)...
January 30, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29386492/-a-case-of-neurolymphomatosis-that-was-diagnosed-by-acoustic-nerve-biopsy
#19
Asuka Asanome, Kohei Kano, Kae Takahashi, Tsukasa Saito, Jun Sawada, Takayuki Katayama
A 58-year-old female was admitted to our hospital because of recurrent multiple cranial neuropathy (right facial palsy followed by involvement of the left trigeminal, facial, acoustic, pharyngeal, and vagal nerves and the right abducens nerve). Brain MRI showed gadolinium enhancement of the right abducens, bilateral facial/acoustic, and left pharyngeal/vagal nerves, and 18F-Fluorodeoxyglucose (FDG)-positron emission tomography revealed abnormal FDG uptake in the right facial, acoustic, pharyngeal, and vagal nerves and the left cervical lymph nodes...
January 31, 2018: Rinshō Shinkeigaku, Clinical Neurology
https://www.readbyqxmd.com/read/29385883/successful-use-of-cytarabine-and-bendamustine-in-a-patient-with-mantle-cell-lymphoma-and-acute-renal-failure-using-intermittent-hemodialysis-a-case-report
#20
Matthew Ettleson, Kale S Bongers, Kaitlyn Vitale, Anthony J Perissinotti, Tycel Phillips, Bernard L Marini
Mantle cell lymphoma is a mature B-cell non-Hodgkin lymphoma characterized by the hallmark (11;14) chromosomal translocation, which often presents with lymphadenopathy and extra-nodal involvement. Young, fit patients are generally treated with chemotherapy approaches that incorporate high-dose cytarabine (e.g. the Nordic regimen) followed by autologous hematopoietic cell transplantation. Because of the significant activity of cytarabine in mantle cell lymphoma, increasingly, high- and intermediate-dose cytarabine are being used in the treatment of elderly mantle cell lymphoma patients...
January 1, 2018: Journal of Oncology Pharmacy Practice
keyword
keyword
36839
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"